Case Report: Anti-LGI1 Encephalitis Following COVID-19 Vaccination

Yair Zlotnik, Avi Gadoth, Ibrahim Abu-Salameh, Anat Horev, Rosa Novoa, Gal Ifergane

    Research output: Contribution to journalArticlepeer-review

    14 Scopus citations


    Anti-leucine rich glioma inactivated 1 (LGI1) autoimmune encephalitis (AE) is characterized by cognitive impairment or rapid progressive dementia, psychiatric disorders, faciobrachial dystonic seizures (FBDS) and refractory hyponatremia. Since December 2020, millions of people worldwide have been vaccinated against COVID-19. Several soft neurological symptoms like pain, headache, dizziness, or muscle spasms are common and self-limited adverse effects after receiving the COVID-19 vaccine. However, several major neurological complications, despite the unproven causality, have been reported since the introduction of the COVID-19 vaccine. Herein, we describe a 48 years old man presenting with rapidly progressive cognitive decline and hyponatremia diagnosed with anti LGI1 AE, occurring shortly after the second dose of mRNA COVID -19 vaccine and possibly representing a severe adverse event related to the vaccination. Response to high dose steroid therapy was favorable. As millions of people worldwide are currently receiving COVID-19 vaccinations, this case should serve to increase the awareness for possible rare autoimmune reactions following this novel vaccination in general, and particularly of anti-LGI1 AE.

    Original languageEnglish
    Article number813487
    JournalFrontiers in Immunology
    StatePublished - 5 Jan 2022


    • COVID-19 vaccination
    • COVID-19 vaccination adverse effect
    • anti-LGI1 autoimmune encephalitis
    • autoimmune encephalitis (AE)
    • case report

    ASJC Scopus subject areas

    • Immunology and Allergy
    • Immunology


    Dive into the research topics of 'Case Report: Anti-LGI1 Encephalitis Following COVID-19 Vaccination'. Together they form a unique fingerprint.

    Cite this